|
Bone metabolism Product details
| Productname |
 OPG |
|
Osteoprotegerin |
| Cat-No. |
BI-20403 |
| Range |
0.3 - 30 pmol/l |
| Sensitivity |
0.07 pmol/l = 1.4 pg/ml |
| Incubation time |
5.5 hours |
| Sample volume |
20 µl |
| Sample type |
Serum, plasma, cell culture |
| Sample preparation |
No activity loss for 8 hours at room temperature or after 2 weeks at
4 °C. Store samples at -20 °C for longer storage. Serum is stable up to 4 freeze and thaw cycles. Hemolyzed or lipemic sera may cause erroneous results. |
| Reference values |
Median = 1,8 pmol/l (n = 1134)
Age 19-96 years |
| Species |
Human, Porcine |
| Tests |
96 |
| Method |
ELISA |
| Product informations |
- Kit Instructions (pdf-File 588 kb)
- Cross-reaction all species (pdf-File 71 kb)
- Bone & Cartilage Metabolism (pdf-File 2480 kb)
|
| Intended use |
Osteoprotegerin (OPG) is a secretory glycoprotein belonging to the TNF receptor super family. OPG inhibits the binding of RANK to RANKL and thus inhibits the recruitment, proliferation and activation of osteoclasts. Since OPG exhibits an inhibitory effect on osteoclasts activation, it acts as a soluble factor in the regulation of bone mass.
Changes in the homeostasis of the RANKL/RANK/OPG systems causes disturbances in bone remodeling shown by bone damages in patients with postmenopausal osteoporosis, Paget’s disease, bone loss due to cancer metastases and rheumatoid arthritis.
Intended applications:
- Postmenopausal and senile osteoporosis
- Glucocorticoid dependent osteoporosis
- Diseases with locally increased resorption activity
- Therapy control of OPG treatments
- Arthritis
- Bone metastases
- Vascular calcification
- Renal cell carcinoma
|
 Back to overview print view |
 |
|
|
